91 results about "Pentamer" patented technology

The disclosed invention relates to general and specific methods to use the Primer Extension / Nick Translation (PENT) reaction to create an amplifiable DNA strand, called a PENTAmer. A PENTAmers can be made for the purpose of amplifying a controlled length of DNA located at a controlled position within a DNA molecule, a process referred to as Positional Amplification by Nick Translation (PANT). In contrast to PCR, which amplifies DNA between two specific sequences, PANT can amplify DNA between two specific positions. PENTAmers can be created to amplify-very large regions of DNA (up to 500,000 bp) as random mixtures (unordered positional libraries), or as molecules sorted according to position (ordered positional libraries). PANT is fast and economical, because PENTAmer preparation can be multiplexed. A single PENTAmer preparation can include very complex mixtures of DNA such as hundreds of large-insert clones, complete genomes, or cDNA libraries. Subsequent PCR amplification of the preparation using a single specific primer can positionally amplify contiguous regions along a specific clone, along a specific genomic region, or along a specific expressed sequence.

The disclosed invention relates to general and specific methods to use the Primer Extension / Nick Translation (PENT) reaction to create an amplifiable DNA strand, called a PENTAmer. A PENTAmers can be made for the purpose of amplifying a controlled length of DNA located at a controlled position within a DNA molecule, a process referred to as Positional Amplification by Nick Translation (PANT). In contrast to PCR, which amplifies DNA between two specific sequences, PANT can amplify DNA between two specific positions. PENTAmers can be created to amplify very large regions of DNA (up to 500,000 bp) as random mixtures (unordered positional libraries), or as molecules sorted according to position (ordered positional libraries). PANT is fast and economical, because PENTAmer preparation can be multiplexed. A single PENTAmer preparation can include very complex mixtures of DNA such as hundreds of large-insert clones, complete genomes, or cDNA libraries. Subsequent PCR amplification of the preparation using a single specific primer can positionally amplify contiguous regions along a specific clone, along a specific genomic region, or along a specific expressed sequence.

The invention provides constant regions incorporating a cysteine mutation and linked to a μ tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and μ tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.

The invention relates to an amino acid sequence of a recombinant human papillomavirus L1 capsid protein, a nucleotide sequence which encodes the amino acid sequence and a recombinant vector and an expression host which contain the nucleotide sequence. The invention further relates to an application of a HPV L1 protein which is composed of the amino acid sequence in the preparation of vaccines, drug combination and diagnostic antigens or antibodies. The invention allows the recombinant HPV L1 capsid protein which is expressed in a prokaryotic system to be dissolvable in water by the modification of the HPV L1 wild-type sequence, and an L1 pentamer which has the same immunogenicity and antigenicity with the VLP of HPV L1 is obtained by expression. The invention allows the industrial production of the HPV L1 capsid protein by utilizing the prokaryotic expression system to become a reality, compared with the currently used eukaryotic expression system, the invention has the advantages of more stable quality of the products, higher yield, low cost and convenient quality control, which has great economic benefits and social effects.

IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.

The invention provides constant regions incorporating a cysteine mutation and linked to a μ tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and μ tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.

IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.

The present invention provides aniline oligomers, their aliphatic polyester copolymer and their preparation. Two kinds of aniline oligomers are first synthesized with N-phenyl-1, 4-p-phenylene diamine as material, and then copolymerized with aliphatic polyester to obtain electrically active biodegradable polymers. During the preparation, N-phenyl-1, 4-p-phenylene diamine has its end amido group protected with butanedioic anhydride and is then reacted with end amido aniline dimer and phenylene diamine to obtain aniline tetramer with one end carboxyl group and one end amino group and aniline pentamer with two end carboxyl groups; and the aniline oligomers are finally polycondensated with double hydroxyl group terminated aliphatic polyester to obtain the copolymers containing electrically active aniline oligomer block. The copolymers possess the advantages of both aniline oligomer and aliphatic polyester, and is used as biomedicine material mainly.

The invention discloses a recombinant helicobacter pylori protein vaccine and a preparation method thereof. The active ingredient recombinant fusion protein of the vaccine consists of recombinant LTAl-Ureal protein and LTB protein, the amino acid sequence of the recombinant LTAl-Ureal protein is shown as Seq ID No.1, the amino acid sequence of the LTB protein is shown as Seq ID No.2. Epitope-containing gene segments of Hp urease A subunit is inserted in an LTA subunit-encoded gene, a toxic part-containing segment is replaced to prepare a recombinant plasmid so as to express and obtain recombinant fusion protein polymer as a vaccine antigen, the fusion antigen and LTB protein pentamer are combined to form a hexamer structure, so that not only can the structure basis and activity of an LT mucosa adjuvant be remained, but also the toxicity can be removed, the immune response of organism muscosa can be effectively induced through immunity of mucosa path, to generate specific IgA antibody. The recombinant helicobacter pylori protein vaccine provides a vaccine manner for preventing and treating infection of helicobacter pylori.

A heteropentamer composed of a fusion monomer (32) comprising a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein and a nonfusion monomer (20) of an amino acid sequence of a monomer of a mucous membrane-binding protein. A homopentamer composed of a fusion monomer including a fusion protein of an antigen derived from an envelope protein of Japanese encephalitis virus and an amino acid sequence of a monomer of a mucous membrane-binding protein. These heteropentamer and the homopentamer can be used as a vaccine.

The invention belongs to the field of immunodetection and discloses a method for the quantitative determination of specific cytotoxicityT lymphocyte of hepatitis B virus. The method adopts the technical proposal that the major histocompatibility compound of antigen peptide pentamer, a mouse anti-human CD3 monoclonal antibody and a mouse anti-human CD8 monoclonal antibody which are labeled by different fluoresceins are incubated with the anticoagulant peripheral blood of an HLA-A0201 or HLA-A2402 positive masculine hepatitis B virus carrier for a proper period; and after the operations of hematid schizolysis, centrifugal washing and cell fixation are completed, the CD3 gating technique is used for the quantitative determination of the specific cytotoxicityT lymphocyte of hepatitis B virus on a flow cytometry. The invention can increase the determination of the specificity, the sensitivity and the stability of the specific CTL.

An emulsion which has an average particle diameter of 100 nm or smaller and comprises: (D) a polyglycerol / fatty acid ester which has an HLB of 13 or higher and in which the polyglycerol is one in which the average degree of polymerization is 8 to 12, the total content of the pentamer and hexamer is 50% by weight or higher, and the total content of the tetramer and lower polymers is less than 20% by weight, and the fatty acid residue is C14-22 hydrocarbon group; (E) a polyglycerol / fatty acid ester which has an HLB of 5 to 11 and in which the polyglycerol is one in which the average degree of polymerization is 2 to 12, the total content of the tetramer and lower polymers is 20% by weight or higher, each of (2 / 3)n components being contained in an amount of at least 5% by weight or more, where n (n is 2 or more) is taken to be an average degree of polymerization (when (2 / 3)n is not a natural number, (2 / 3)n is considered to be a lowest natural number greater than (2 / 3)n), and the fatty acid residue is a C14-22 hydrocarbon group; (F) a lecithin; and (G) an oily ingredient.

The invention provides a preparation method of high-activity zinc phthalocyanine-monoclonal antibody tumor-targeted photosensitive immunoconjugate and a technical method for anti-tumor application of the immunoconjugate. Monocarboxyl zinc phthalocyanine with a single structure is reacted with lysine hydrazine pentamer to form a water-soluble monocarboxyl zinc phthalocyanine hydrazine derivative with high reaction activity; meanwhile, the monoclonal antibody with anti-tumor activity is selected; under a neutral condition, glycosyl non-related to activity of the antibody is mildly oxidized into an aldehyde group with sodium periodate; and at 4 DEG C, excess monocarboxyl zinc phthalocyanine hydrazine derivative is extremely easy for reacting with the aldehyde group and the reaction product is further reduced into stable photosensitive immunoconjugate to obtain the high-purity photosensitive immunoconjugate. The preparation method has the characteristics of low temperature, neutral conditions and no use of any organic solvent. In-vitro anti-tumor experiments prove that the conjugate has extremely high selectivity and anti-tumor activity as well as application value.

A protein nanofiber comprised of self-assembling pentamers, and a method for producing the protein nanofiber, in which the protein upon which the nanofiber is based is a specific form of COMP. The proteins self-assemble via electrostatic interactions to form fibers that extend longitudinally.

IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.

The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and Cμ3 and Cμ4 regions of a Cμ constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a Cμ constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.

The invention discloses a nano-composite material used for tissue repair, which comprises segmented copolymer with electrical activity, nano-hydroxyapatite and normal tissue repair materials; wherein the segmented copolymer comprises aliphatic polyester and ailine pentamer, and the normal tissue repair materials comprises poly (lactide-co-glycolide), polylactide or polycaprolactone. The invention also discloses a preparation method of the nano-composite materials used for tissue repair, which comprises the following steps of: (a) dissolving the normal tissue repair material in a solvent, then adding the nano-hydroxyapatite into the solvent, and uniformly stirring to obtain a substrate material; and (b) dissolving the segmented copolymer into the solvent, then adding to the substrate material and mixing uniformly, and then precipitating and removing the solvent. The nano-composite material used for the tissue repair has the advantages of nontoxicity, biodegradability, processibility, sufficient mechanical strength, favorable electrical activity, and biocompatibility.

The invention relates to a virus-like particle (VLP) of a recombined human papillomavirus (HPV) 33 and a preparation method of the virus-like particle. According to the specific technical key points, a polynucleotide gene segment of a new coded and recombined HPV33 L1 protein, a carrier containing the gene segment, a host cell comprising the carrier, an HPV33 L1 fusion protein translated and expressed by the gene segment, a pentamer and the VLP consisting of the pentamer are provided. The invention furthermore discloses applications of the pentamer, a VLP protein and a vaccine composition consisting of the pentamer and the VLP protein to the preparation of drugs for preventing HPV33 infection.

The invention discloses synthesis method of a five-membered flower cyclic supramolecule based on terpyridyl metal coordination. The supermolecule is a giant five-membered flower ring-shaped supermolecule formed by self-driving a ligand containing a plurality of terpyridyl and metal ruthenium and transition metal ions in a solvent, wherein the ligand and the transition metal can accurately react togenerate a single pentamer product without generation of other byproducts; then structural characterization and molecular weight determination are carried out on the ligand and a final assembly product through nuclear magnetism, mass spectrometry, scanning electron microscopy and other tests. The supermolecule has large molecular weight and good solubility, the molecular structure has symmetry and aesthetic properties, and gelation can be realized.

The invention relates to a recombinant VLP of HPV31 and a preparation method thereof. Specifically, the invention discloses a novel polynucleotide gene segment coding recombinant HPV31 L1 protein, a vector containing the gene segment, a host cell containing the vector, HPV31 L1 fusion protein translated and expressed by the gene segment, a pentamer and a VLP composed of the pentamer; and the invention also discloses application of the pentamer, VLP protein and a vaccine composition composed of the pentamer and the VLP protein in preparation of drugs used for preventing HPV31 infection.

A heteropentamer composed of a fusion monomer (32) comprising a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein and a nonfusion monomer (20) of an amino acid sequence of a monomer of a mucous membrane-binding protein. A homopentamer composed of a fusion monomer including a fusion protein of an antigen derived from an envelope protein of Japanese encephalitis virus and an amino acid sequence of a monomer of a mucous membrane-binding protein. These heteropentamer and the homopentamer can be used as a vaccine.

The invention provides a polynucleotides gene fragment of recombinant human papilloma virus type 33 L1 protein, a carrier containing the gene fragment, a host cell containing the comprise, and a HPV33L1 protein pentamer expressed by the gene fragment and an anti-HPV type 33 infection vaccine composed of the pentamer.

The invention relates to a recombinant human papilloma virus 16L1 protein and its use, and provides a new polynucleotides gene fragment coding the recombinant HPV16L1 protein, a vector containing the gene fragment, a host cell containing the vector, an HPV16L1 protein pentamer expressed by the gene fragment in translation, and an anti-HPV16 infection cervical carcinoma vaccine composed of the pentamer.

Various processes are disclosed for preparing protected epicatechin oligomers having (4β,8)-interflavan linkages. In one process, a tetra-O-protected epicatechin monomer or oligomer is coupled with a protected, C-4 activated epicatechin monomer in the presence of an acidic clay such as a mortmorillonite clay. In another process, a 5,7,3′,4′-benzyl protected or a 3-acetyl-, 5,7,3′,4′-benzyl protected epicatechin or catechin monomer or oligomer is reacted with 3-O-acetyl-4-[(2-benzothiazolyl)thio]-5,7,3′,4′-tetra-O-benzylepicatechin in the presence of silver tetrafluoroborate. In another process, two 5,7,3′,4′-benzyl protected epicatechin monomers activated with 2-(benzothiazolyl)thio groups at the C-4 positions are cross-coupled in the presence of silver tetrofluoroborate. A process is also disclosed for reacting an unprotected epicatechin or catechin monomer with 4-(benzylthio)epicatechin or catechin. The use of naturally-derived and synthetically-prepared procyanidin (4β,8)4-pentamers to treat cancer is also disclosed.

The invention discloses morinda officinalis oligosaccharides and a preparation method therefor. The oligosaccharide content is 50-99%. The morinda officinalis oligosaccharides comprise dimers, trimers, tetramers, pentamers, hexamers, heptamers, octamers and nonamers. The morinda officinalis oligosaccharides has a function of ajdusting immunization. The preparation method can achieve industrialization production.

The invention relates to an application of pentamer lysinephthalocyanine zinc in killing staphylococcus aureus. The pentamer lysinephthalocyanine zinc are taken as the main component for killing staphylococcus, and a phosphate buffer solution and a medical surfactant are added as auxiliary agents to prepare a drug for killing staphylococcus aureus. The drug has the advantages that the main component has a definite structure with the purity reaching more than 98 percent, and has a good water solubility; the drug can be specially combined with cell membranes of bacteria, is low in use concentration, and has small toxicity on human embryonic lung fibroblast and skin; and when the concentration of the pentamer lysinephthalocyanine zinc is greater than 5 mu M, as long as a light source with excitation wavelength of 670 nm is used to radiate for 2 minutes, more than 99.99 percent of staphylococcus aureus can be killed. Thepentamer lysinephthalocyanine zinc has a good application prospect.

The invention provides a method for oligomerization of alpha-olefin based on a microchannel reaction. The method comprises that aluminum trichloride is modified through an organic acid in the presenceof a halogenated hydrocarbon as a solvent, wherein after the modification reaction of aluminum trichloride, the modified aluminum trichloride has good solubility and is uniformly dispersed in the halogenated hydrocarbon, and alpha-olefin as a starting raw material is preheated, is efficiently mixed and fast reacts in the presence of the uniform aluminum trichloride dispersed system as a catalystin a microchannel reactor, wherein the temperature in the reaction channel is 50-150 DEG C, pressure in the reaction channel is 0-20 MPa, staying time is 30-600s and a mass ratio of aluminum trichloride to alpha-olefin is 0.5-5%. In the product, trimer, tetramer and pentamer (lubricating base oil ideal component) selectivity is 95%. Through aluminum trichloride modification, organic dispersibilityis obtained. The method is suitable for a microchannel continuous reaction and has the advantages of high-efficiency mass transfer, stable temperature control and easy regulation and control of product selectivity.

The invention provides a novel polynucleotide gene segment of coded recombinant protein HPV6L1, a vector containing the gene segment, a host cell containing the vector, a protein HPV6L1 pentamer obtained by translating and expressing the gene segment, and an HPV6 infection-resistant condyloma acuminate vaccine consisting of the pentame.

The invention relates to a recombinant human papilloma virus 18L1 protein and its use, and provides a new polynucleotides gene fragment coding the recombinant HPV18L1 protein, a vector containing the gene fragment, a host cell containing the vector, an HPV18L1 protein pentamer expressed by the gene fragment in translation, and an anti-HPV18 infection condyloma acuminatum vaccine composed of the pentamer.